

L27

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1 ✓	4 S BEPRIDIL
L2 ✓	22 S VERAPAMIL
L3 ✓	32 S NIFEDIPINE
L4 ✓	5 S NISOLDIPINE
L5 ✓	0 S THEPHYLLINE
L6 ✓	2485 S THEOPHYLLINE —
L7 ✓	1 S SEMECARPUS ANACARDIUM
L8 ✓	74 S VITAMIN E
L9	162 S PAPAVERINE
L10	3 S DESDANINE

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000

	E ALTZHEIMER
	E ALZHEIMER
L11	15731 S E3-E5
	E DEMENTIA
L12	4671 S E3-E6
	E SENILE
L13	17527 S E3 OR L11
L14	2881 S L12 AND L13

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Feb	2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec	17	Expanded CAPLUS Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Feb	1	Addition of Machine-Translated Abstracts to CAPLUS
NEWS	4	Feb	28	Patent Information Now Searchable in CAOLD
NEWS	5	May	1	RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS	6	May	22	CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS	7	May	22	POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED BY ADDITION OF CITED REFERENCES TO CAPLUS, CA, REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS	8	Jun	2	KOREAN PATENTS NOW IN CAS DATABASES
NEWS	9	Jun	20	WIPO/PCT Patents Fulltext Database now on STN
NEWS	10	Jun	28	CAS covers Web-distributed preprints
NEWS	11	Jul	7	Patent Full-text Cluster, PNTTEXT, introduced
NEWS	12	Jul	27	EUROPATFULL - loading of backlog data
NEWS	13	Jul	27	MORE FREQUENT UPDATES FOR DERWENT WORLD PATENTS INDEX IN 2000
NEWS	14	Jul	27	Derwent Journal Of Synthetic Methods Reloaded with New Data
NEWS	15	Jul	27	DERWENT WORLD PATENTS INDEX: FAST TRACK RELEASE OF EQUIVALENT PATENTS
NEWS EXPRESS				FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS				STN Operating Hours Plus Help Desk Availability
NEWS INTER				General Internet Information
NEWS LOGIN				Welcome Banner and News Items
NEWS PHONE				Direct Dial and Telecommunication Network Access to STN
NEWS WWW				CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

*LDPCI - Derwent Patents Citation Index Learning File

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

0.30

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 15 AUG 2000 HIGHEST RN 286364-83-8

DICTIONARY FILE UPDATES: 15 AUG 2000 HIGHEST RN 286364-83-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> s bepridil

L1 4 BEPRIDIL

=> d l1 1

L1 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2000 ACS

RN 110143-75-4 REGISTRY.

CN 1-Pyrrolidineethanamine, .beta.-[(2-methylpropoxy)methyl]-N-phenyl-N-
(phenylmethyl)-, (-)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN **(-)-Bepridil**

FS STEREOSEARCH


MF C24 H34 N2 O

SR CA

LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOSIS, CA, CAPLUS, DRUGPAT,
DRUGUPDATES, TOXLIT

(*File contains numerically searchable property data)

Rotation (-).



14 REFERENCES IN FILE CA (1967 TO DATE)


14 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s verapamil

L2 22 VERAPAMIL

=> d 12 1

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2000 ACS
RN 154670-15-2 REGISTRY
CN Benzeneacetonitrile,
.alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propy
1]-3,5-dimethoxy-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetonitrile,
.alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propy
1]-3,5-dimethoxy-.alpha.-(1-methylethyl)-, (.+-.)-
OTHER NAMES:
CN **Racemic norverapamil**
FS 3D CONCORD
MF C26 H36 N2 O4
SR CA
LC STN Files: CA, CAPLUS, TOXLIT



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s nifedipine

L3 32 NIFEDIPINE

=> d 13 1

L3 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2000 ACS
RN 205330-56-9 REGISTRY
CN **DNA (human intestine gene CYP3A4 nifedipine oxidase cDNA plus flanks)**
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN DNA (human intestine gene CYP3A4 cytochrome P 450 cDNA plus flanks)
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d 13 32

L3 ANSWER 32 OF 32 REGISTRY COPYRIGHT 2000 ACS
RN 21829-25-4 REGISTRY

CN 3,5-Pyridinedicarboxylic acid,
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-
, dimethyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 3,5-Pyridinedicarboxylic acid,
1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-
, dimethyl ester (8CI)

OTHER NAMES:

CN 2,6-Dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-1,4-dihydropyridine
CN 2,6-Dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid
dimethyl ester

CN Adalat

CN BAY 1040

CN BAY-a 1040

CN Cordafen

CN Cordaflex

CN Corinfar

CN Corynphar

CN Dimethyl 4-(o-Nitrophenyl)-2,6-dimethyl-1,4-dihydro-3,5-
pyridinedicarboxylate

CN Fenihidine

CN Glopil

CN **Nifedipine**

CN Niphedipine

CN Procardia

CN Procardia XL

CN TN 873R

FS 3D CONCORD

DR 11104-22-6, 101539-70-2, 101554-38-5

MF C17 H18 N2 O6


CI COM

LC STN Files: ADISINSIGHT, AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
DETERM*, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDIRECTORY,
IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO,
TOXLINE, TOXLIT, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



5821 REFERENCES IN FILE CA (1967 TO DATE)

80 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

5828 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s nisoldipine

L4

5 NISOLDIPINE

=> d 14 5

L4 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2000 ACS

RN 63675-72-9 REGISTRY

CN 3,5-Pyridinedicarboxylic acid,
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-
, methyl 2-methylpropyl ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-BAY k 5552

CN (.+-.)-**Nisoldipine**

CN BAY-k 5552

CN **Nisoldipine**

FS 3D CONCORD

DR 86189-67-5

MF C20 H24 N2 O6


CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,
CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IFICDB, IFIPAT,
IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*, TOXLINE,
TOXLIT, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



704 REFERENCES IN FILE CA (1967 TO DATE)

9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

706 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s thephylline

L5 0 THEPHYLLINE

=> s theophylline

L6 2485 THEOPHYLLINE

=> d 16 2485

L6 ANSWER 2485 OF 2485 REGISTRY COPYRIGHT 2000 ACS

RN 58-08-2 REGISTRY


CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Caffeine (8CI)

OTHER NAMES:

CN 1,3,7-Trimethyl-2,6-dioxopurine
 CN 1,3,7-Trimethylxanthine
 CN 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
 CN **7-Methyltheophylline**
 CN Alert-Pep
 CN Cafeina
 CN Caffein
 CN Cafipel
 CN Guaranine
 CN Koffein
 CN Mateina
 CN Methyltheobromine
 CN No-Doz
 CN Refresh'n
 CN Stim
 CN Thein
 CN Theine
 CN Tri-Aqua
 FS 3D CONCORD
 DR 95789-13-2, 71701-02-5
 MF C8 H10 N4 O2
 CI COM
 LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS,
 BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*,
 DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB,
 IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA,
 PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, ULIDAT, USAN, USPATFULL,
 VETU,
 VTB
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



13344 REFERENCES IN FILE CA (1967 TO DATE)
 142 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 13367 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s semecarpus anacardium

1 SEMECARPUS
 4 ANACARDIUM
 L7 1 SEMECARPUS ANACARDIUM
 (SEMECARPUS (W) ANACARDIUM)

=> d 17

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2000 ACS
 RN 90106-74-4 REGISTRY *
 * Use of this CAS Registry Number alone as a search term in other STN files
 may
 result in incomplete search results. For additional information, enter HELP
 RN* at an online arrow prompt (=>).
 CN **Semecarpus anacardium, ext.** (CA INDEX NAME)
 DEF Extractives and their physically modified derivatives such as tinctures,
 concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free
 fractions, distillates, residues, etc., obtained from Semecarpus
 anacardium, Anacardiaceae.
 MF Unspecified
 CI MAN, CTS
 SR Commission of European Communities
 LC STN Files: CHEMLIST, TOXLINE
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> s vitamin e


1215 VITAMIN
 552148 E
 L8 74 VITAMIN E
 (VITAMIN(W)E)

=> s papaverine

L9 162 PAPAVERINE

=> d 19 162

L9 ANSWER 162 OF 162 REGISTRY COPYRIGHT 2000 ACS
 RN 58-74-2 REGISTRY
 CN Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy- (9CI) (CA
 INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI)
 OTHER NAMES:
 CN 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline
 CN 6,7-Dimethoxy-1-veratrylisoquinoline
 CN Papaverin
 CN **Papaverine**
 FS 3D CONCORD
 DR 85702-67-6, 47446-64-0
 MF C20 H21 N O4
 CI COM
 LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS,
 BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU,
 EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXLINE,
 TOXLIT, TULSA, USAN, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



2839 REFERENCES IN FILE CA (1967 TO DATE)
 45 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2840 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s desdanine

L10 3 DESDANINE

=> d 110 3

L10 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2000 ACS
 RN 11012-92-3 REGISTRY
 CN **Desdanine, monohydrochloride (8CI)** (CA INDEX NAME)
 FS STEREOSEARCH
 MF C7 H10 N2 O . Cl H
 LC STN Files: CAOLD
 CRN (35663-85-5)

Double bond geometry as shown.



● HCl

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file ca

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	58.68	58.98

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 11 Aug 2000 VOL 133 ISS 8
FILE LAST UPDATED: 11 Aug 2000 (20000811/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CA on STN.

=> e altzheimer

E1	1	ALTYUZ/BI
E2	2	ALTZ/BI
E3	6 -->	ALTZHEIMER/BI
E4	2383	ALU/BI
E5	1	ALU0/BI
E6	15	ALU1/BI
E7	1	ALU156/BI
E8	1	ALU197/BI
E9	1	ALU1P/BI
E10	6	ALU2/BI
E11	1	ALU216/BI
E12	1	ALU24/BI

=> e alzheimer

E1	1	ALZH1A/BI
E2	1	ALZHEEIMER/BI
E3	15709 -->	ALZHEIMER/BI
E4	1	ALZHEIMERC/BI
E5	1281	ALZHEIMERS/BI
E6	1	ALZHEIMNER/BI
E7	2	ALZHEIMR/BI
E8	1	ALZHEIMWE/BI
E9	1	ALZHEINER/BI
E10	1	ALZHEIZER/BI
E11	1	ALZHEMER/BI
E12	1	ALZHEMERS/BI

=> s e3-e5

	15709	ALZHEIMER/BI
	1	ALZHEIMERC/BI
	1281	ALZHEIMERS/BI
L11	15731	(ALZHEIMER/BI OR ALZHEIMERC/BI OR ALZHEIMERS/BI)

=> e dementia

E1	2	DEMENTHYLATED/BI
E2	1	DEMENTHYLATION/BI
E3	4600 -->	DEMENTIA/BI
E4	1	DEMENTIAASSOCD/BI
E5	10	DEMENTIAL/BI
E6	239	DEMENTIAS/BI
E7	1	DEMENTIC/BI
E8	1	DEMENTII/BI
E9	85	DEMENTING/BI
E10	2	DEMENTION/BI
E11	1	DEMENTIONAL/BI
E12	1	DEMENTJEV/BI

=> s e3-e6

	4600	DEMENTIA/BI
	1	DEMENTIAASSOCD/BI
	10	DEMENTIAL/BI
	239	DEMENTIAS/BI
L12	4671	(DEMENTIA/BI OR DEMENTIAASSOCD/BI OR DEMENTIAL/BI OR DEMENTIAS/B
		I)

=> e senile

E1	1	SENILAC/BI
E2	1	SENILAX/BI
E3	3672 -->	SENILE/BI
E4	1	SENILEPLAQUES/BI
E5	6	SENILES/BI
E6	2	SENILIA/BI
E7	1	SENILILE/BI
E8	1	SENILIN/BI
E9	1	SENILINE/BI
E10	41	SENILIS/BI
E11	14491	SENILITY/BI
E12	2	SENILLA/BI

=> s e3 or l11

	3672	SENILE/BI
L13	17527	SENILE/BI OR L11

=> s l12 and l13

L14	2881	L12 AND L13
-----	------	-------------

=> d his

(FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1	4	S BEPRIDIL
L2	22	S VERAPAMIL
L3	32	S NIFEDIPINE
L4	5	S NISOLDIPINE
L5	0	S THEPHYLLINE
L6	2485	S THEOPHYLLINE
L7	1	S SEMECARPUS ANACARDIUM
L8	74	S VITAMIN E
L9	162	S PAPAVERINE
L10	3	S DESDANINE

E ALTZHEIMER
 E ALZHEIMER
 L11 15731 S E3-E5
 E DEMENTIA
 L12 4671 S E3-E6
 E SENILE
 L13 17527 S E3 OR L11
 L14 2881 S L12 AND L13

=> s 11

L15 464 L1

=> s 115 and 114

L16 0 L15 AND L14

=> s 11 and 114

464 L1
 L17 0 L1 AND L14

=> s 12 and 114

8272 L2
 L18 1 L2 AND L14

=> d 118

L18 ANSWER 1 OF 1 CA COPYRIGHT 2000 ACS

AN 110:225483 CA

TI Treatment of nervous system degeneration with dehydroepiandrosterone and its sulfate

IN Roberts, Eugene

PA City of Hope, USA

SO U.S., 6 pp. Cont. of U.S. Ser. No. 790,080, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4812447	A	19890314	US 1986-940789	19861211
PRAI	US 1985-790080		19851022		

=> s 11 and 111

464 L1
 L19 0 L1 AND L11

=> s 13 and 114

5986 L3
 L20 1 L3 AND L14

=> d 120

L20 ANSWER 1 OF 1 CA COPYRIGHT 2000 ACS

AN 119:80228 CA
 TI Synergistic combination of calcium antagonists with cholinesterase inhibitors for treatment of **senile dementia**
 IN De Jonge, Maarten
 PA Troponwerke G.m.b.H. und Co. K.-G., Germany
 SO Ger. Offen., 6 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4136288	A1	19930506	DE 1991-4136288	19911104
	EP 547334	A1	19930623	EP 1992-118040	19921022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	CA 2081808	AA	19930505	CA 1992-2081808	19921030
	JP 05221877	A2	19930831	JP 1992-315594	19921102
PRAI	DE 1991-4136288		19911104		

=> d 120 all

L20 ANSWER 1 OF 1 CA COPYRIGHT 2000 ACS
 AN 119:80228 CA
 TI Synergistic combination of calcium antagonists with cholinesterase inhibitors for treatment of **senile dementia**
 IN De Jonge, Maarten
 PA Troponwerke G.m.b.H. und Co. K.-G., Germany
 SO Ger. Offen., 6 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM A61K031-44
 ICS A61K031-66; A61K031-645; A61K031-40
 ICI A61K031-44, A61K031-66, A61K031-645, A61K031-40
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4136288	A1	19930506	DE 1991-4136288	19911104
	EP 547334	A1	19930623	EP 1992-118040	19921022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	CA 2081808	AA	19930505	CA 1992-2081808	19921030
	JP 05221877	A2	19930831	JP 1992-315594	19921102
PRAI	DE 1991-4136288		19911104		

GI



AB Ca2+ antagonists I [X, Y = H, NO2, halo, or XY complete a benzoxadiazolyl group; R1, R2 = (un)substituted C1-6 alkyl, N-benzylpiperidin-3-yl; Z = H, OCH2CH2NH2] synergistically enhance the memory-improving effect of cholinesterase inhibitors in patients with **senile dementia**, esp. **Alzheimer's** disease. Thus, metrifonate (1 mg/kg) and nimodipine (1.0-10.0 mg/kg orally), administered to rats 45 and 30 min before testing, resp., improved their performance in a conditioned avoidance test.

ST calcium antagonist **dementia** treatment cholinesterase inhibitor; **Alzheimer** treatment calcium antagonist cholinesterase inhibitor; metrifonate nimodipine memory

IT Memory, biological
(acetylcholinesterase inhibitor and calcium antagonist improvement of, in **senile dementia**)

IT Mental disorder
(**Alzheimer's** disease, treatment of, with acetylcholinesterase inhibitor and calcium antagonist)

IT Ion channel blockers
(calcium, **senile dementia** treatment with acetylcholinesterase inhibitor and)

IT Mental disorder
(**senile** psychosis, treatment of, with acetylcholinesterase inhibitor and calcium antagonist)

IT 9000-81-1, Acetylcholinesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors, **senile dementia** treatment with calcium antagonist and)

IT **21829-25-4**, Nifedipine 39562-70-4, Nitrendipine 63675-72-9, Nisoldipine 66085-59-4, Nimodipine
RL: BIOL (Biological study)
(**senile dementia** treatment with acetylcholinesterase inhibitor and)

IT 3295-64-5D, derivs. 7664-38-2D, Phosphoric acid, esters 149099-82-1D, derivs. 149099-83-2
RL: BIOL (Biological study)
(**senile dementia** treatment with calcium antagonist and)

=> s 14 and 114

734 L4
L21 1 L4 AND L14

=> d 121

L21 ANSWER 1 OF 1 CA COPYRIGHT 2000 ACS

AN 119:80228 CA

TI Synergistic combination of calcium antagonists with cholinesterase inhibitors for treatment of **senile dementia**

IN De Jonge, Maarten

PA Troponwerke G.m.b.H. und Co. K.-G., Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4136288	A1	19930506	DE 1991-4136288	19911104

EP 547334 A1 19930623 EP 1992-118040 19921022
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE
 CA 2081808 AA 19930505 CA 1992-2081808 19921030
 JP 05221877 A2 19930831 JP 1992-315594 19921102
 PRAI DE 1991-4136288 19911104

=> s 16 and 114

25639 L6
 L22 3 L6 AND L14

=> d 122 1-3

L22 ANSWER 1 OF 3 CA COPYRIGHT 2000 ACS
 AN 132:18799 CA
 TI Use of a NK-1 receptor antagonist for treating psychiatric disorders
 IN Rupniak, Nadia Melanie
 PA Merck Sharp & Dohme Limited, UK
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964006	A1	19991216	WO 1999-GB1797	19990608
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9942781	A1	19991230	AU 1999-42781	19990608
PRAI	GB 1998-12616		19980611		
	GB 1998-12618		19980611		
	GB 1998-12620		19980611		
	GB 1998-12666		19980611		
	WO 1999-GB1797		19990608		

RE.CNT 7

RE
 (1) Merck Sharp & Dohme; WO 9518124 A 1995
 (2) Merck Sharp & Dohme; WO 9815277 A 1998
 (3) Merck Sharp & Dohme; WO 9824438 A 1998
 (4) Merck Sharp & Dohme; WO 9824439 A 1998
 (5) Merck Sharp & Dohme; WO 9824440 A 1998
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 3 CA COPYRIGHT 2000 ACS
 AN 130:205539 CA
 TI Method and compositions for promoting the neural synthesis and release of neurotransmitters using neurotransmitter precursors in combination with xanthines
 IN Shell, William E.; Jarmel, Mark E.
 PA Nicada, Inc., USA
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908681	A1	19990225	WO 1998-US16882	19980813
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9891975	A1	19990308	AU 1998-91975	19980813
PRAI	US 1997-55732		19970813		
	US 1998-133660		19980812		
	WO 1998-US16882		19980813		

RE.CNT 4

RE

- (1) Blum; US 4761429 A 1988
- (2) Blum; US 5189064 A 1993
- (3) Hutterer; US 4837219 A 1989 CA
- (4) Wurtman; US 5096712 A 1992

L22 ANSWER 3 OF 3 CA COPYRIGHT 2000 ACS

AN 114:164265 CA

TI Preparation of xanthines as adenosine antagonists

IN Kuefner-Muehl, Ulrike; Weber, Karl Heinz; Walther, Gerhard; Stransky, Werner; Ensinger, Helmut; Schingnitz, Guenter; Kuhn, Franz Josef; Lehr, Erich

PA Boehringer Ingelheim K.-G., Fed. Rep. Ger.

SO Ger. Offen., 20 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3843117	A1	19900628	DE 1988-3843117	19881222
	EP 374808	A2	19900627	EP 1989-123412	19891218
	EP 374808	A3	19910515		
	EP 374808	B1	19960424		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 136897	E	19960515	AT 1989-123412	19891219
	ES 2086313	T3	19960701	ES 1989-123412	19891219
	SK 279525	B6	19981202	SK 1989-7197	19891219
	DD 290421	A5	19910529	DD 1989-335983	19891220
	PL 162877	B1	19940131	PL 1989-282878	19891220
	FI 96513	B	19960329	FI 1989-6117	19891220
	FI 96513	C	19960710		
	CA 2006387	AA	19900622	CA 1989-2006387	19891221
	DK 8906526	A	19900623	DK 1989-6526	19891221
	NO 8905168	A	19900625	NO 1989-5168	19891221
	NO 173502	B	19930913		
	NO 173502	C	19931222		
	HU 52503	A2	19900728	HU 1989-6736	19891221
	ZA 8909881	A	19910828	ZA 1989-9881	19891221
	IL 92829	A1	19951231	IL 1989-92829	19891221
	AU 8947072	A1	19900628	AU 1989-47072	19891222
	AU 637990	B2	19930617		
	JP 02247180	A2	19901002	JP 1989-334668	19891222
	JP 2565576	B2	19961218		
	US 5175291	A	19921229	US 1991-691193	19910425
	RU 2057752	C1	19960410	RU 1992-5011448	19920507

US 5532368	A	19960702	US 1993-97478	19930727
US 5696124	A	19971209	US 1995-454452	19950530
US 5688802	A	19971118	US 1996-663417	19960614

PRAI DE 1988-3843117 19881222
 US 1989-452643 19891218
 US 1991-691193 19910425
 US 1992-942871 19920910
 US 1993-97478 19930727
 OS MARPAT 114:164265

=> s 14 and 111

L23 734 L4
 5 L4 AND L11

=> d his

(FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1	4 S BEPRIDIL
L2	22 S VERAPAMIL
L3	32 S NIFEDIPINE
L4	5 S NISOLDIPINE
L5	0 S THEPHYLLINE
L6	2485 S THEOPHYLLINE
L7	1 S SEMECARPUS ANACARDIUM
L8	74 S VITAMIN E
L9	162 S PAPAVERINE
L10	3 S DESDANINE

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000

	E ALTZHEIMER
	E ALZHEIMER
L11	15731 S E3-E5
	E DEMENTIA
L12	4671 S E3-E6
	E SENILE
L13	17527 S E3 OR L11
L14	2881 S L12 AND L13
L15	464 S L1
L16	0 S L15 AND L14
L17	0 S L1 AND L14
L18	1 S L2 AND L14
L19	0 S L1 AND L11
L20	1 S L3 AND L14
L21	1 S L4 AND L14
L22	3 S L6 AND L14
L23	5 S L4 AND L11

=> s 123 not 121

L24 4 L23 NOT L21

=> d 124 1-4

L24 ANSWER 1 OF 4 CA COPYRIGHT 2000 ACS
 AN 133:99570 CA
 TI Treatment of hypertension with compounds that inhibit the destruction of
 enkephalins or endorphins

IN Ehrenpreis, Seymour; Blum, Kenneth
PA USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000041686	A1	20000720	WO 2000-US722	20000112
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-115724 19990112

RE.CNT 5

RE

- (1) Flynn; US 5238932 A 1993 CA
- (2) Rabkin, S; Can J Physiol Pharmacol 1989, V67(8), P857 CA
- (3) Thompson; US 5425954 A 1995 CA
- (4) Warshawsky; US 5420271 A 1995 CA
- (5) Zhao, J; Beijing Yike Daxue Xuebao 1991, V23(3), P170 CA

L24 ANSWER 2 OF 4 CA COPYRIGHT 2000 ACS

AN 132:88204 CA

TI Method of treatment and pharmaceutical composition using
valsartan-calcium

channel blocker combination

IN De Gasparo, Marc; Webb, Randy Lee

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft
m.b.H.

SO PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000002543	A2	20000120	WO 1999-EP4842	19990709
	WO 200002543	A3	20000629		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

AU 9950349 A1 20000201

AU 1999-50349 19990709

PRAI US 1998-113893 19980710

WO 1999-EP4842 19990709

L24 ANSWER 3 OF 4 CA COPYRIGHT 2000 ACS

AN 124:97758 CA

TI Drug combination containing .alpha.-lipoic acid and cardiovascular agents

IN Weischer, Carl; Ulrich, Heinz; Conrad, Frank; Schmidt, Karlheinz

PA ASTA Medica AG, Germany

SO Ger. Offen., 18 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 4420102	A1	19951214	DE 1994-4420102	19940609

L24 ANSWER 4 OF 4 CA COPYRIGHT 2000 ACS

AN 122:89432 CA

TI Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists

IN Inada, Yoshiyuki; Kubo, Keiji

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 628313	A1	19941214	EP 1994-108687	19940607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07053373	A2	19950228	JP 1994-124838	19940607
	JP 3057471	B2	20000626		
	EP 753301	A1	19970115	EP 1996-115146	19940607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
PRAI	JP 1993-135524		19930607		
	EP 1994-108687		19940607		
OS	MARPAT 122:89432				

=> s 16 and 111

25639 L6

L25 20 L6 AND L11

=> d his

(FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1	4 S	BEPRIDIL
L2	22 S	VERAPAMIL
L3	32 S	NIFEDIPINE
L4	5 S	NISOLDIPINE
L5	0 S	THEOPHYLLINE
L6	2485 S	THEOPHYLLINE
L7	1 S	SEMECARPUS ANACARDIUM
L8	74 S	VITAMIN E
L9	162 S	PAPAVERINE
L10	3 S	DESDANINE

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000

	E	ALZHEIMER
	E	ALZHEIMER
L11	15731 S	E3-E5
	E	DEMENTIA
L12	4671 S	E3-E6
	E	SENILE
L13	17527 S	E3 OR L11

L14 2881 S L12 AND L13
 L15 464 S L1
 L16 0 S L15 AND L14
 L17 0 S L1 AND L14
 L18 1 S L2 AND L14
 L19 0 S L1 AND L11
 L20 1 S L3 AND L14
 L21 1 S L4 AND L14 -
 L22 3 S L6 AND L14 - *scribble + Theophylline*
 L23 5 S L4 AND L11
 L24 4 S L23 NOT L21
 L25 20 S L6 AND L11

=> s 125 not 122

L26 17 L25 NOT L22

=> d 126 1-17

L26 ANSWER 1 OF 17 CA COPYRIGHT 2000 ACS

AN 133:68575 CA

TI Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists:
the Cache County Study

AU Anthony, J. C.; Breitner, J. C. S.; Zandi, P. P.; Meyer, M. R.; Jurasova,
I.; Norton, M. C.; Stone, S. V.; Burke, James; Calvert, Tony; Gau,
Barbara; Helms, Michael; Khachaturian, Ara; Leslie, Carole; Newman,
Tiffany; Plassman, Brenda; Steffens, David C.; Steinberg, Martin;

Tschanz,

JoAnn Welsh-Bohmer, Kathleen; West, Nancy; Wyse, Bonita

CS Cache County Memory Study Group, Department of Mental Hygiene, School of
Hygiene and Public Health, Johns Hopkins University, Baltimore, MD, USA

SO Neurology (2000), 54(11), 2066-2071

CODEN: NEURAI; ISSN: 0028-3878

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 26

RE

(1) Andersen, K; Neurology 1995, V45, P1441 CA

(10) Kawas, C; Neurology 1997, V48, P1517 CA

(11) LaFerla, F; J Clin Invest 1997, V100, P310 CA

(12) Launer, L; Neurobiol Aging 1997, V18, P257 CA

(13) Mattson, M; J Neurochem 1998, V70, P1 CA

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 2 OF 17 CA COPYRIGHT 2000 ACS

AN 132:75459 CA

TI Process for identifying compounds which protect against the formation of
fluorescent light induced DNA lesions and x-ray-induced lesions

IN Parshad, Ram; Sanford-Mifflin, Katherine K.; Robbins, Jay H.; Boone,
Charles W.

PA The United States of America, Department of Health and Human Services,
USA

SO U.S., 14 pp., Cont.-in-part of U.S. 5,773,219.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6017706	A	20000125	US 1997-852355	19970507
	US 5773219	A	19980630	US 1996-611330	19960308

PRAI US 1992-957315 19921006
US 1994-228825 19940418
US 1996-611330 19960308

RE.CNT 26

RE

- (1) Antoccia, A; Int J Radiat Biol 1997, V71(1), P41 CA
- (4) Gantt, R; Cancer Research 1987, V47, P1390 CA
- (5) Grossman; US 4975365 1990 CA
- (6) Iversen; US 5641754 1997 CA
- (12) Parshad, R; Cancer Res 1980, V40, P4415 CA

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 17 CA COPYRIGHT 2000 ACS

AN 131:725 CA

TI Inhibitors of nitric oxide synthase, proinflammatory cytokine inhibitors,
and therapeutic use

IN Singh, Inderjit

PA Medical University of South Carolina, USA

SO PCT Int. Appl., 209 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926657	A1	19990603	WO 1998-US25360	19981125
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9915393	A1	19990615	AU 1999-15393	19981125
PRAI	US 1997-66839		19971125		
	US 1997-66295		19971125		
	WO 1998-US25360		19981125		

RE.CNT 6

RE

- (1) Denhardt; US 5695761 A 1997 CA
- (2) Gross; US 5545625 A 1996
- (3) Harrison; US 5498539 A 1996 CA
- (5) Pahan; Journal Clinical Investigation 1997, V100, P2671 CA
- (6) Societe De Conseils De Recherches Et D'Application Scientifiques; WO 98/09653 A1 1998 CA

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 17 CA COPYRIGHT 2000 ACS

AN 130:10276 CA

TI Caffeine based measures of CYP 1A2 activity correlate with oral clearance
of tacrine in patients with **Alzheimer's** disease

AU Fontana, Robert J.; deVries, Tina M.; Woolf, Thomas F.; Knapp, Margaret
J.; Brown, As; Kaminsky, Laurence S.; Tang, Bing-Kuo; Foster, Norman L.;
Brown, Richard R.; Watkins, Paul B.

CS Department of Internal Medicine, University of Michigan, Ann Arbor, MI,
48109, USA

SO Br. J. Clin. Pharmacol. (1998), 46(3), 221-228

CODEN: BCPHBM; ISSN: 0306-5251

PB Blackwell Science Ltd.

DT Journal

LA English

RE.CNT 48

RE

- (2) Becquemont, L; Clin Pharmacol Ther 1997, V61, P619 CA
- (3) Becquemont, L; Fundam Clin Pharm 1996, V10, P156 CA
- (4) Butler, M; Pharmacogenetics 1992, V2, P116 CA
- (5) Butler, M; Proc Natl Acad Sci USA 1989, V86, P7696 CA

L26 ANSWER 5 OF 17 CA COPYRIGHT 2000 ACS

AN 129:273607 CA

TI Expression of ryanodine receptors in human embryonic kidney (HEK293) cells

AU Querfurth, Henry W.; Haughey, Norman J.; Greenway, Steven C.; Yacono, Patrick W.; Golan, David E.; Geiger, Jonathan D.

CS Departments of Neurology and Biomedical Research, St. Elizabeth's Medical Center, Boston, MA, 02135, USA

SO Biochem. J. (1998), 334(1), 79-86

CODEN: BIJOAK; ISSN: 0264-6021

PB Portland Press Ltd.

DT Journal

LA English

L26 ANSWER 6 OF 17 CA COPYRIGHT 2000 ACS

AN 129:166193 CA

TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix

IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot;

Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas

R.; Roberts, F. Donald; Friden, Phil

PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.

SO PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1997-789734		19970127		
	WO 1998-US1556		19980127		

L26 ANSWER 7 OF 17 CA COPYRIGHT 2000 ACS

AN 129:104229 CA

TI Nornicotine enantiomers for use as a treatment for dopamine-related conditions and disease states

IN Crooks, Peter A.; Dwoskin, Linda Phyliss; Bardo, Michael Thomas

PA University of Kentucky Research Foundation, USA

SO U.S., 40 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5776957	A	19980707	US 1996-749404	19961115

L26 ANSWER 8 OF 17 CA COPYRIGHT 2000 ACS

AN 129:38398 CA

TI Process for detecting **Alzheimer** disease using cultured cells

IN Sanford-Mifflin, Katherine K.; Parshad, Ram; Robbins, Jay H.

PA United States Dept. of Health and Human Services, USA

SO U.S., 19 pp. Cont.-in-part of U. S. Ser. No. 228,825, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5773219	A	19980630	US 1996-611330	19960308
	US 6017706	A	20000125	US 1997-852355	19970507
PRAI	US 1992-957315		19921006		
	US 1994-228825		19940418		
	US 1996-611330		19960308		

L26 ANSWER 9 OF 17 CA COPYRIGHT 2000 ACS

AN 127:261228 CA

TI Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases

AU Luo, Yuan; Bond, Joshua D.; Ingram, Vernon M.

CS Dep. Biology, Massachusetts Inst. Tech., Cambridge, MA, 02139, USA

SO Proc. Natl. Acad. Sci. U. S. A. (1997), 94(18), 9705-9710

CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

L26 ANSWER 10 OF 17 CA COPYRIGHT 2000 ACS

AN 126:14770 CA

TI Alkaline and acid phosphatase inhibitors in treatment of neurological disorders

IN Kelleher, Judith A.; Eveleth, David D.

PA Cortex Pharmaceuticals, Inc., USA

SO U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 71,281, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5567724	A	19961022	US 1994-252109	19940601
PRAI	US 1993-71281		19930601		

L26 ANSWER 11 OF 17 CA COPYRIGHT 2000 ACS

AN 125:27041 CA

TI Fluorescent light-induced chromatid breaks distinguish **Alzheimer** disease cells from normal cells in tissue culture

AU Parshad, Ram; Sanford, Katherine K.; Price, Floyd M.; Melnick, Lynn K.;

Nee, Linda E.; Schapiro, Mark B.; Tarone, Robert E.; Robbins, Jay H.

CS Coll. Med., Howard Univ., Washington, DC, 20059, USA

SO Proc. Natl. Acad. Sci. U. S. A. (1996), 93(10), 5146-5150

CODEN: PNASA6; ISSN: 0027-8424

DT Journal

LA English

L26 ANSWER 12 OF 17 CA COPYRIGHT 2000 ACS

AN 122:123145 CA

TI Alkaline and acid phosphatase inhibitors in treatment of neurological disorders

IN Kelleher, Judith A.; Eveleth, David D., Jr.

PA Cortex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9427603	A1	19941208	WO 1994-US6186	19940601
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9470506	A1	19941220	AU 1994-70506	19940601
	AU 698101	B2	19981022		
	EP 701441	A1	19960320	EP 1994-919323	19940601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE					
PRAI	US 1993-71281		19930601		
	WO 1994-US6186		19940601		

L26 ANSWER 13 OF 17 CA COPYRIGHT 2000 ACS

AN 122:89432 CA

TI Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists

IN Inada, Yoshiyuki; Kubo, Keiji

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 628313	A1	19941214	EP 1994-108687	19940607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07053373	A2	19950228	JP 1994-124838	19940607
	JP 3057471	B2	20000626		
	EP 753301	A1	19970115	EP 1996-115146	19940607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
PRAI	JP 1993-135524		19930607		
	EP 1994-108687		19940607		
OS	MARPAT 122:89432				

L26 ANSWER 14 OF 17 CA COPYRIGHT 2000 ACS

AN 122:72050 CA

TI Apoptosis inhibitors for treating neurodegenerative diseases

IN Rubin, Lee Laurence; Brooks, Susan Frances

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9427583	A2	19941208	WO 1994-GB1169	19940531
	WO 9427583	A3	19950202		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 700286	A1	19960313	EP 1994-916326	19940531
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				

SE

JP 09504780 T2 19970513 JP 1994-500413 19940531
US 5840719 A 19981124 US 1996-556974 19960508
PRAI GB 1993-11132 19930528
WO 1994-GB1169 19940531

L26 ANSWER 15 OF 17 CA COPYRIGHT 2000 ACS

AN 120:315801 CA

TI A method of screening compounds for treating **Alzheimer's**
disease, and diagnostic and treatment methods

IN Wolozin, Benjamin L.; Sunderland, Trey

PA United States Dept. of Health and Human Services, USA

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9407144	A1	19940331	WO 1993-US8969	19930921
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1992-948408		19920921		

L26 ANSWER 16 OF 17 CA COPYRIGHT 2000 ACS

AN 118:139763 CA

TI Caffeine and nicotine improve visual tracking by rats: A comparison with
amphetamine, cocaine and apomorphine

AU Evenden, J. L.; Turpin, M.; Oliver, L.; Jennings, C.

CS Merck Sharpe and Dohme Neurosci. Res. Cent., Harlow/Essex, UK

SO Psychopharmacology (Berlin) (1993), 110(1-2), 169-76

CODEN: PSCHDL; ISSN: 0033-3158

DT Journal

LA English

L26 ANSWER 17 OF 17 CA COPYRIGHT 2000 ACS

AN 115:205090 CA

TI Studies on choline transport enhancement into fibroblasts from normals
and

Alzheimer's donors

AU Mokrasch, Lewis Carl

CS Med. Cent., Louisiana State Univ., New Orleans, LA, 70119, USA

SO Neurochem. Res. (1991), 16(7), 757-61

CODEN: NEREDZ; ISSN: 0364-3190

DT Journal

LA English

=> s 114 or 111

L27 16091 L14 OR L11

=> s 18 d his

MISSING OPERATOR L8 D HIS

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d his

(FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1 4 S BEPRIDIL
 L2 22 S VERAPAMIL
 L3 32 S NIFEDIPINE
 L4 5 S NISOLDIPINE
 L5 0 S THEPHYLLINE
 L6 2485 S THEOPHYLLINE
 L7 1 S SEMECARPUS ANACARDIUM
 L8 74 S VITAMIN E
 L9 162 S PAPAVERINE
 L10 3 S DESDANINE

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000

E ALTZHEIMER
 E ALZHEIMER
 L11 15731 S E3-E5
 E DEMENTIA
 L12 4671 S E3-E6
 E SENILE
 L13 17527 S E3 OR L11
 L14 2881 S L12 AND L13
 L15 464 S L1
 L16 0 S L15 AND L14
 L17 0 S L1 AND L14
 L18 1 S L2 AND L14
 L19 0 S L1 AND L11
 L20 1 S L3 AND L14
 L21 1 S L4 AND L14
 L22 3 S L6 AND L14
 L23 5 S L4 AND L11
 L24 4 S L23 NOT L21
 L25 20 S L6 AND L11
 L26 17 S L25 NOT L22
 L27 16091 S L14 OR L11

=> s 17 and 127

0 L7
 L28 0 L7 AND L27

=> s 17

L29 0 L7

=> s 18 and 111

21237 L8
 L30 94 L8 AND L11

=> d 130 70-94

L30 ANSWER 70 OF 94 CA COPYRIGHT 2000 ACS

AN 125:265738 CA

TI Rationale and design of a multicenter study of selegiline and
 .alpha.-tocopherol in the treatment of **Alzheimer** disease using
 novel clinical outcomes

AU Sano, Mary; Ernesto, Christopher; Klauber, Melville R.; Schafer,
 Kimberly;

Woodbury, Peter; Thomas, Ronald; Grundman, Michael; Growdon, John; Thal,
 Leon J.

CS College Physicians and Surgeons, Columbia University, New York, NY, USA

SO Alzheimer Dis. Assoc. Disord. (1996), 10(3), 132-140

CODEN: ADADE2; ISSN: 0893-0341

DT Journal
LA English

L30 ANSWER 71 OF 94 CA COPYRIGHT 2000 ACS

AN 125:238515 CA

TI Actions of neurotoxic .beta.-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants

AU Zhou, Yan; Gopalakrishnan, Venkat; Richardson, J. Steven

CS Department of Pharmacology, Univ. Saskatchewan, Saskatoon, SK, Can.

SO J. Neurochem. (1996), 67(4), 1419-1425

CODEN: JONRA9; ISSN: 0022-3042

DT Journal

LA English

L30 ANSWER 72 OF 94 CA COPYRIGHT 2000 ACS

AN 125:204564 CA

TI Pharmaceutical compositions containing haloperidol, imipramine or trifluoroperazine

IN Bleiweiss, Eduardo Samuel; Bleiweiss, Daniel Gustavo; Bleiweiss, Herman

PA Argent.

SO Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 726073	A2	19960814	EP 1996-101771	19960207
	EP 726073	A3	19980708		
	R: DE, FR, GB, IT				
	CA 2169247	AA	19960811	CA 1996-2169247	19960209
	US 5837701	A	19981117	US 1996-599294	19960209
	JP 09020666	A2	19970121	JP 1996-49498	19960213
PRAI	AR 1995-330996		19950210		

L30 ANSWER 73 OF 94 CA COPYRIGHT 2000 ACS

AN 125:96165 CA

TI Liposome composition containing selegilin

IN Mezii, Michael; Goal, Jozsef; Szekais, Gabor; Szebeni, Gyula; Marmarosi,

Tamasne; Mogyau, Kalman; Lengyel, Jozsef; Szotmari, Istvan; Turi, Agnes

PA Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt, Hung.

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9612472	A1	19960502	WO 1995-HU52	19951020
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF				
	HU 76053	A2	19970630	HU 1994-3073	19941024
	CA 2203513	AA	19960502	CA 1995-2203513	19951020
	AU 9537518	A1	19960515	AU 1995-37518	19951020
	AU 691348	B2	19980514		
	EP 788349	A1	19970813	EP 1995-935530	19951020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	CN 1163563	A	19971029	CN 1995-195853	19951020
	BR 9509517	A	19971230	BR 1995-9517	19951020
	JP 10507749	T2	19980728	JP 1995-513742	19951020

ZA 9508999	A	19960515	ZA 1995-8999	19951024
IL 115754	A1	19990714	IL 1995-115754	19951024
FI 9701743	A	19970423	FI 1997-1743	19970423
NO 9701870	A	19970624	NO 1997-1870	19970423
US 5888536	A	19990330	US 1997-817433	19970805
PRAI HU 1994-3073		19941024		
HU 1994-307394		19941024		
WO 1995-HU52		19951020		

L30 ANSWER 74 OF 94 CA COPYRIGHT 2000 ACS

AN 125:96100 CA

TI Monofunctional and/or polyfunctional polylysine conjugates for treatment of neural disorders, autoimmune diseases, and proliferative diseases

IN Geffard, Michel

PA Fr.

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9615810	A1	19960530	WO 1995-FR1517	19951117
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2727117	A1	19960524	FR 1994-13861	19941118
	FR 2727117	B1	19970221		
	CA 2205557	AA	19960530	CA 1995-2205557	19951117
	AU 9641811	A1	19960617	AU 1996-41811	19951117
	EP 792167	A1	19970903	EP 1995-940329	19951117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	JP 10511643	T2	19981110	JP 1995-516622	19951117
PRAI	FR 1994-13861		19941118		
	WO 1995-FR1517		19951117		

L30 ANSWER 75 OF 94 CA COPYRIGHT 2000 ACS

AN 125:84634 CA

TI Porcine striatal cells and their use in treatment of neurological deficits

due to neurodegenerative disease

IN Isacson, Ole; Dinsmore, Jonathan

PA Mclean Hospital Corporation, USA; The Mclean Hospital Corporation

SO PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614399	A1	19960517	WO 1995-US14453	19951107
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2204429	AA	19960517	CA 1995-2204429	19951107
	AU 9641486	A1	19960531	AU 1996-41486	19951107
	AU 715092	B2	20000113		
	EP 791054	A1	19970827	EP 1995-939806	19951107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				

SE

JP 10508488 T2 19980825 JP 1995-515488 19951107
 PRAI US 1994-336856 19941108
 US 1995-424851 19950419
 WO 1995-US14453 19951107

L30 ANSWER 76 OF 94 CA COPYRIGHT 2000 ACS

AN 125:83715 CA

TI Porcine cortical cells and their use in treatment of neurological deficits

due to neurodegenerative diseases

IN Dinsmore, Jonathan

PA Diacrin, Inc., USA

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614397	A1	19960517	WO 1995-US14451	19951107
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2204428	AA	19960517	CA 1995-2204428	19951107
	AU 9641484	A1	19960531	AU 1996-41484	19951107
	AU 715186	B2	20000120		
	EP 791052	A1	19970827	EP 1995-939804	19951107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				

SE

JP 10509034 T2 19980908 JP 1995-515486 19951107

PRAI US 1994-336856 19941108

US 1995-424856 19950419

WO 1995-US14451 19951107

L30 ANSWER 77 OF 94 CA COPYRIGHT 2000 ACS

AN 125:83714 CA

TI Porcine mesencephalic cells and their use in treatment of neurological deficits due to neurodegenerative diseases

IN Fraser, Thomas; Dinsmore, Jonathan

PA Diacrin, Inc., USA

SO PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614398	A1	19960517	WO 1995-US14452	19951107
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2204427	AA	19960517	CA 1995-2204427	19951107
	AU 9641485	A1	19960531	AU 1996-41485	19951107
	EP 791053	A1	19970827	EP 1995-939805	19951107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				

SE

JP 10508487 T2 19980825 JP 1995-515487 19951107

PRAI US 1994-336856 19941108

US 1995-424855 19950419

WO 1995-US14452 19951107

L30 ANSWER 78 OF 94 CA COPYRIGHT 2000 ACS

AN 124:285973 CA

TI Endogenous **Alzheimer's** brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor

AU Frey, William H., II; Najarian, Melissa M.; Kumar, Kavita S.; Emory, Carolyn R.; Menning, Patrick M.; Frank, John C.; Johnson, Melissa N.;

Ala,

Thomas A.

CS Department of Neurology, The Alzheimer's Treatment and Research Center, Ramsey Clinic/St. Paul Ramsey Medical Center, 640 Jackson Street, St. Paul, MN, 55101-2595, USA

SO Brain Res. (1996), 714(1,2), 87-94
CODEN: BRREAP; ISSN: 0006-8993

DT Journal

LA English

L30 ANSWER 79 OF 94 CA COPYRIGHT 2000 ACS

AN 124:250846 CA

TI Amphiphilic .alpha.-tocopherol analogs as inhibitors of brain lipid peroxidation

AU Bolkenius, Frank N.; Verne-Mismer, Joeelle; Wagner, Joseph; Grisar, J. Martin

CS Marion Merrell Dow Research Institute, 16 Rue d'Ankara, Strasbourg, F-67080, Fr.

SO Eur. J. Pharmacol. (1996), 298(1), 37-43
CODEN: EJPHAZ; ISSN: 0014-2999

DT Journal

LA English

L30 ANSWER 80 OF 94 CA COPYRIGHT 2000 ACS

AN 123:102794 CA

TI Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomatology.

IN Shapiro, Howard K.

PA USA

SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9501096	A1	19950112	WO 1994-US7277	19940628
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5668117	A	19970916	US 1993-62201	19930629
	AU 9472144	A1	19950124	AU 1994-72144	19940628
	AU 692454	B2	19980611		
	EP 707446	A1	19960424	EP 1994-921405	19940628
	R: DE, FR, GB, IT				
	JP 08512055	T2	19961217	JP 1994-503597	19940628
PRAI	US 1993-62201		19930629		
	US 1991-660561		19910222		
	US 1993-26617		19930223		
	WO 1994-US7277		19940628		

L30 ANSWER 81 OF 94 CA COPYRIGHT 2000 ACS

AN 123:40968 CA

TI Combination of sugars with amino acids and other drugs

IN Naito, Albert

PA USA

SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI EP 652012 A1 19950510 EP 1993-308852 19931105
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
 SE

L30 ANSWER 82 OF 94 CA COPYRIGHT 2000 ACS

AN 123:7163 CA

TI The concentrations of .alpha.-tocopherol and .alpha.-tocopherolquinone in the cerebrospinal fluid in patients with neurodegenerative disease

AU Saheki, Mika; Abe, Takashi; Takahashi, Satoshi

CS Sch. Med., Iwate Med. Univ., Morioka, 020, Japan

SO Iwate Igaku Zasshi (1995), 47(1), 51-9

CODEN: IIZAAX; ISSN: 0021-3284

DT Journal

LA Japanese

L30 ANSWER 83 OF 94 CA COPYRIGHT 2000 ACS

AN 123:6768 CA

TI Change of radical scavengers in patients with **Alzheimer**-type dementia

AU Kobayashi, Kazunari; Kosaka, Kenji

CS Dep. Psychiatry, Natl. Yokohama Hosp., Yokohama, 245, Japan

SO Dementia (Osaka) (1995), 9(2), 162-72

CODEN: DEMEE3; ISSN: 0913-6835

DT Journal; General Review

LA Japanese

L30 ANSWER 84 OF 94 CA COPYRIGHT 2000 ACS

AN 122:142506 CA

TI Use of hydrophilic carotenoids for the treatment of diseases having an oxidation mechanism

IN Howard, Alan Norman; Hepworth, Lawrence; Thurnham, David I.

PA Howard Foundation, UK

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9500130	A1	19950105	WO 1994-GB1402	19940628
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9470056	A1	19950117	AU 1994-70056	19940628
	GB 2280110	A1	19950125	GB 1994-12938	19940628
	GB 2280110	B2	19971112		
	ZA 9404633	A	19951025	ZA 1994-4633	19940628
PRAI	GB 1993-13266		19930628		
	US 1994-219897		19940330		
	WO 1994-GB1402		19940628		

L30 ANSWER 85 OF 94 CA COPYRIGHT 2000 ACS

AN 122:46272 CA

TI Inhibitors of free radical formation fail to attenuate direct .beta.-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures

AU Lockhart, B. P.; Benicourt, C.; Junien, J.-L.; Privat, A.

CS INSERM U-336, Ec. Natl. Super. Chim., Montpellier, Fr.

SO J. Neurosci. Res. (1994), 39(4), 494-505

CODEN: JNREDK; ISSN: 0360-4012

DT Journal
LA English

L30 ANSWER 86 OF 94 CA COPYRIGHT 2000 ACS

AN 121:246338 CA

TI Superoxide dismutase gene mutations as causes of neurodegenerative diseases and compounds and methods for the diagnosis, treatment, and prevention of the diseases

IN Brown, Robert; Horvitz, H. Robert; Rosen, Daniel R.

PA General Hospital Corp., USA; Massachusetts Institute of Technology

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9419493	A1	19940901	WO 1994-US2089	19940228
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5843641	A	19981201	US 1993-23980	19930226
	CA 2157041	AA	19940901	CA 1994-2157041	19940228
	EP 686203	A1	19951213	EP 1994-910183	19940228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE	JP 08510377	T2	19961105	JP 1994-519309	19940228
	US 5849290	A	19981215	US 1995-486953	19950607
PRAI	US 1993-23980	19930226			
	US 1994-204052	19940228			
	WO 1994-US2089	19940228			

L30 ANSWER 87 OF 94 CA COPYRIGHT 2000 ACS

AN 121:131488 CA

TI Concentrations of .alpha.-tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the

Binswanger

type and **Alzheimer** type dementia

AU Tohgi, Hideo; Abe, Takashi; Nakanishi, Mika; Hamato, Fumitoshi; Sasaki, Kazuhiro; Takahashi, Satoshi

CS Department of Neurology, Iwate Medical University, 19-1 Uchimaru, Morioka,

020, Japan

SO Neurosci. Lett. (1994), 174(1), 73-6

CODEN: NELED5; ISSN: 0304-3940

DT Journal

LA English

L30 ANSWER 88 OF 94 CA COPYRIGHT 2000 ACS

AN 121:921 CA

TI Method of preventing NMDA receptor complex-mediated neuronal damage with nitroso compound

IN Lipton, Stuart A.

PA Children's Medical Center Corp., USA

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9406428	A1	19940331	WO 1993-US9019	19930922
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

US 5234956	A	19930810	US 1992-949342	19920922
US 5455279	A	19951003	US 1993-25028	19930302
EP 661973	A1	19950712	EP 1993-923724	19930922
R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
US 6071876	A	20000606	US 1998-138580	19980821

PRAI US 1992-949342 19920922
US 1993-25028 19930302
US 1991-688965 19910419
WO 1993-US9019 19930922
US 1995-482365 19950607

L30 ANSWER 89 OF 94 CA COPYRIGHT 2000 ACS
AN 120:86441 CA
TI Synergistic combinations comprising lipoic acid and vitamins in pharmaceuticals
IN Weischer, Carl Heinz; Ulrich, Heinz; Klaus, Wessel
PA ASTA Medica AG, Germany
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	EP 572922	A1	19931208	EP 1993-108574	19930527
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE					
	DE 4218572	A1	19931209	DE 1992-4218572	19920605
	CA 2097732	AA	19931206	CA 1993-2097732	19930604
	JP 06135832	A2	19940517	JP 1993-134402	19930604
	US 5569670	A	19961029	US 1995-404153	19950314
PRAI	DE 1992-4218572		19920605		
	US 1993-71259		19930604		
	US 1994-194643		19940210		

L30 ANSWER 90 OF 94 CA COPYRIGHT 2000 ACS
AN 118:247608 CA
TI Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E
AU Maneesub, Yawadee; Sanvarinda, Yupin; Govitrapong, Piyaarat
CS Inst. Sci. Technol. Dev., Mahidol Univ., Thailand
SO Neurochem. Int. (1993), 22(5), 487-91
CODEN: NEUIDS; ISSN: 0197-0186
DT Journal
LA English

L30 ANSWER 91 OF 94 CA COPYRIGHT 2000 ACS
AN 117:126120 CA
TI Vitamin E protects nerve cells from amyloid .beta. protein toxicity
AU Behl, Christian; Davis, John; Cole, Greg M.; Schubert, David
CS Salk Inst. Biol. Stud., San Diego, CA, 92186-5800, USA
SO Biochem. Biophys. Res. Commun. (1992), 186(2), 944-50
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

L30 ANSWER 92 OF 94 CA COPYRIGHT 2000 ACS
AN 117:87891 CA
TI **Alzheimer's** and Parkinson's Disease. Brain levels of glutathione, glutathione disulfide, and vitamin E.
AU Adams, James D., Jr.; Klaidman, Lori K.; Odunze, Ifeoma N.; Shen, Howard C.; Miller, Carol A.
CS Sch. Med., Univ. South. California, Los Angeles, CA, 90033, USA

SO Mol. Chem. Neuropathol. (1991), 14(3), 213-26
CODEN: MCHNEM
DT Journal
LA English

L30 ANSWER 93 OF 94 CA COPYRIGHT 2000 ACS
AN 112:116708 CA
TI Vitamin E concentrations in human brain of patients with **Alzheimer**
's disease, fetuses with Down's syndrome, centenarians, and controls
AU Metcalfe, T.; Bowen, D. M.; Muller, D. P. R.
CS Dep. Child Health, Inst. Child Health, London, WC1N 1EH, UK
SO Neurochem. Res. (1989), 14(12), 1209-12
CODEN: NEREDZ; ISSN: 0364-3190
DT Journal
LA English

L30 ANSWER 94 OF 94 CA COPYRIGHT 2000 ACS
AN 109:66857 CA
TI Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes:
effect of glutathione and vitamin E
AU Dogterom, Peter; Nagelkerke, J. Fred; Mulder, Gerard J.
CS Cent. Bio-Pharm. Sci., Univ. Leiden, Leiden, 2300 RA, Neth.
SO Biochem. Pharmacol. (1988), 37(12), 2311-13
CODEN: BCPA6; ISSN: 0006-2952
DT Journal
LA English

=> d 130 91 90 84 all

L30 ANSWER 91 OF 94 CA COPYRIGHT 2000 ACS
AN 117:126120 CA
TI Vitamin E protects nerve cells from amyloid .beta. protein toxicity
AU Behl, Christian; Davis, John; Cole, Greg M.; Schubert, David
CS Salk Inst. Biol. Stud., San Diego, CA, 92186-5800, USA
SO Biochem. Biophys. Res. Commun. (1992), 186(2), 944-50
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
CC 4-3 (Toxicology)
Section cross-reference(s): 6, 14
AB Amyloid .beta. protein (ABP) and an internal fragment encompassing
residues 25 to 35 (.beta.25-35) are cytotoxic to a clone of PC12 cells at
concns. above 1x10⁻⁹M and to several other cell lines at higher concns.
Between 10⁻⁹ and 10⁻¹¹M .beta.25-35 protects PC12 cells from glutamate
toxicity. The antioxidant and free radical scavenger vitamin E inhibits
ABP-induced cell death. These results have implications regarding the
prevention and treatment of **Alzheimer's** disease.
ST amyloid toxicity nerve vitamin E
IT Nerve, toxic chemical and physical damage
(amyloid .beta.-protein toxicity to, vitamin E effect on, fragment
toxicity in relation to)
IT Proteins, specific or class
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(amyloid A4, toxicity of, to nerve, vitamin E effect on, fragment
toxicity in relation to)
IT 121-79-9, Propyl gallate **1406-18-4**, Vitamin E 9061-61-4, Nerve
growth factor
RL: BIOL (Biological study)
(amyloid .beta.-protein toxicity to nerve in relation to)
IT 56-86-0, Glutamic acid, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

L30 ANSWER 90 OF 94 CA COPYRIGHT 2000 ACS
AN 118:247608 CA
TI Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E
AU Maneesub, Yawadee; Sanvarinda, Yupin; Govitrapong, Piyarat
CS Inst. Sci. Technol. Dev., Mahidol Univ., Thailand
SO Neurochem. Int. (1993), 22(5), 487-91
CODEN: NEUIDS; ISSN: 0197-0186
DT Journal
LA English
CC 1-12 (Pharmacology)
AB It has been suggested that the activity of the enzyme responsible for the synthesis of acetylcholine, choline acetyltransferase (ChAT), is substantially reduced in the neocortex and hippocampus of **Alzheimer's** and other aging brains. d-.alpha.-Tocopherol (vitamin E), a free radical scavenger fat-sol. vitamin, was utilized in the present study to det. whether its supplementation in aging and ethylcholine mustard aziridinium (AF64A)-lesioned rats would improve the cholinergic hypofunction. Vitamin E (given 24 h and 15 min prior to AF64A administration) significantly ($P < 0.01$) reversed the effect of AF64A in hippocampal choline acetyltransferase activity, but it did not cause any change of this enzyme activity in other brain regions (striatum and frontal cortex), nor did it cause any significant change after 30-day daily treatment in AF64A-lesioned rats. Furthermore, vitamin E (50 mg/kg, i.p. for 30-day treatment) significantly ($P < 0.01$) partially restored the enzyme activity in striatum of aging (20-28 mo old) rats. The present result indicates that vitamin E can partly restore the hypofunction of the cholinergic system in aging and partly prevent the toxicity in AF64A-lesioned rats.
ST brain lesion cholinergic deficit vitamin E; aging brain cholinergic deficit vitamin E; choline acetyltransferase brain lesion vitamin E
IT Senescence
(brain choline acetyltransferase deficit in, vitamin E restoration of),
IT Brain, disease
(lesion, choline acetyltransferase deficit in, vitamin E restoration of, senescence in relation to)
IT 59-02-9, d-.alpha.-Tocopherol
RL: BIOL (Biological study)
(choline acetyltransferase deficit in brain lesions restoration by, senescence in relation to)
IT 9012-78-6, Choline acetyltransferase
RL: BIOL (Biological study)
(decrease of, in brain lesions, vitamin E partial restoration of, senescence in relation to)

L30 ANSWER 84 OF 94 CA COPYRIGHT 2000 ACS
AN 122:142506 CA
TI Use of hydrophilic carotenoids for the treatment of diseases having an oxidation mechanism
IN Howard, Alan Norman; Hepworth, Lawrence; Thurnham, David I.
PA Howard Foundation, UK
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-07
CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9500130	A1	19950105	WO 1994-GB1402	19940628
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9470056	A1	19950117	AU 1994-70056	19940628
	GB 2280110	A1	19950125	GB 1994-12938	19940628
	GB 2280110	B2	19971112		
	ZA 9404633	A	19951025	ZA 1994-4633	19940628
PRAI	GB 1993-13266		19930628		
	US 1994-219897		19940330		
	WO 1994-GB1402		19940628		
AB	Lutein and other hydrophilic carotenoids are disclosed for use in the treatment of diseases having an oxidn. mechanism. The carotenoids disclosed are esp. useful in treatment of coronary heart diseases and may be combined with e.g. aspirin.				
ST	carotenoid organ oxidative damage treatment				
IT	Antioxidants				
	(biol.; carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Antidiabetics and Hypoglycemics				
	Cataract				
	Down's syndrome				
	Neoplasm inhibitors				
	Parkinsonism				
	Senescence				
	(carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Deoxyribonucleic acids				
	Lipids, biological studies				
	Lipoproteins				
	Proteins, biological studies				
	RL: BSU (Biological study, unclassified); BIOL (Biological study)				
	(carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Carotenes and Carotenoids, biological studies				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Inflammation inhibitors				
	Radical ions				
	(carotenoids in combination with other antioxidants or anti-inflammatory agents for treatment of diseases having oxidn. mechanism)				
IT	Reactive oxygen species				
	RL: BSU (Biological study, unclassified); BIOL (Biological study)				
	(carotenoids in combination with other antioxidants or anti-inflammatory agents for treatment of diseases having oxidn. mechanism)				
IT	Mental disorder				
	(Alzheimer's disease, carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Inflammation inhibitors				
	(antirheumatics, carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Brain, disease				
	(cerebrovascular, carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Heart, disease				
	(coronary, carotenoids for treatment of diseases having oxidn. mechanism)				
IT	Cardiovascular system				

(disease, carotenoids for treatment of diseases having oxidn. mechanism)

IT 116-30-3 126-29-4, Violaxanthin 127-40-2, Lutein 144-68-3, Zeaxanthin 432-70-2, .alpha.-Carotene 465-42-9, Capsanthin 470-38-2, Capsorubin 472-61-7, Astaxanthin 472-70-8, .beta.-Cryptoxanthin 472-73-1, Eschscholtz-xanthin 472-92-4, .delta.-Carotene 472-93-5, .gamma.-Carotene 502-65-8, Lycopene 512-29-8, Flavoxanthin 514-76-1, Astacene 514-78-3, Canthaxanthin 640-03-9, Antheraxanthin 752-29-4, Anhydrolutein 3351-86-8, Fucoxanthin 7235-40-7, .beta.-Carotene 24480-38-4, .alpha.-Cryptoxanthin 27785-15-5, Auroxanthin 28368-08-3, Eloxanthin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carotenoids for treatment of diseases having oxidn. mechanism)

IT 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 69-72-7, Salicylic acid, biological studies 303-38-8, 2,3-Dihydroxybenzoic acid 303-98-0, Coenzyme Q10 490-79-9, 2,5-Dihydroxybenzoic acid 1406-18-4, Vitamin E 7439-96-5, Manganese, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7782-49-2, Selenium, biological studies 11103-57-4, Vitamin A

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carotenoids in combination with other antioxidants or anti-inflammatory agents for treatment of diseases having oxidn. mechanism)

=> d his

(FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1 4 S BEPRIDIL
L2 22 S VERAPAMIL
L3 32 S NIFEDIPINE
L4 5 S NISOLDIPINE
L5 0 S THEPHYLLINE
L6 2485 S THEOPHYLLINE
L7 1 S SEMECARPUS ANACARDIUM
L8 74 S VITAMIN E
L9 162 S PAPAVERINE
L10 3 S DESDANINE

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000

E ALTZHEIMER
E ALZHEIMER
L11 15731 S E3-E5
E DEMENTIA
L12 4671 S E3-E6
E SENILE
L13 17527 S E3 OR L11
L14 2881 S L12 AND L13
L15 464 S L1
L16 0 S L15 AND L14
L17 0 S L1 AND L14
L18 1 S L2 AND L14
L19 0 S L1 AND L11
L20 1 S L3 AND L14
L21 1 S L4 AND L14
L22 3 S L6 AND L14
L23 5 S L4 AND L11
L24 4 S L23 NOT L21

L25 20 S L6 AND L11
L26 17 S L25 NOT L22
L27 16091 S L14 OR L11
L28 0 S L7 AND L27
L29 0 S L7
L30 94 S L8 AND L11

=> s 127 and 19

4035 L9
L31 4 L27 AND L9

=> d 131 1-4

L31 ANSWER 1 OF 4 CA COPYRIGHT 2000 ACS

AN 132:189687 CA

TI Biochemical germanium complexes with high therapeutic efficiency and wide application spectrum

IN Soloviev, Evgeny Vladimirovich; Shcherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich; Kotrelev, Mikhail Vladimirovich; Pavlov, Konstantin Vitalevich; Khromova, Nataliya Yurievna; Komalenkova, Nina Georgievna

PA Fr.

SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010561	A1	20000302	WO 1998-EP5214	19980817
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

OS MARPAT 132:189687

RE.CNT 8

RE

- (1) Asai Germanium Kenkyusho; JP 61158989 A 1986
- (2) Goodman, S; Medical Hypotheses 1988, V26(3), P207 CA
- (3) Heteroorganic CPDS Chem Techn Res Inst; SU 1150935 A 1993
- (4) Kakimoto, N; US 4772628 A 1988
- (5) Kuzmin, K; WO 9840103 A 1998

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 4 CA COPYRIGHT 2000 ACS

AN 131:725 CA

TI Inhibitors of nitric oxide synthase, proinflammatory cytokine inhibitors, and therapeutic use

IN Singh, Inderjit

PA Medical University of South Carolina, USA

SO PCT Int. Appl., 209 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 9926657 A1 19990603 WO 1998-US25360 19981125
W: AU, CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
AU 9915393 A1 19990615 AU 1999-15393 19981125
PRAI US 1997-66839 19971125
US 1997-66295 19971125
WO 1998-US25360 19981125

RE.CNT 6

RE

- (1) Denhardt; US 5695761 A 1997 CA
- (2) Gross; US 5545625 A 1996
- (3) Harrison; US 5498539 A 1996 CA
- (5) Pahan; Journal Clinical Investigation 1997, V100, P2671 CA
- (6) Societe De Conseils De Recherches Et D'Application Scientifiques; WO 98/09653 A1 1998 CA

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 3 OF 4 CA COPYRIGHT 2000 ACS

AN 129:325739 CA

TI Discovering transthyretin amyloid fibril inhibitors by limited screening

AU Baures, Paul W.; Peterson, Scott A.; Kelly, Jeffery W.

CS Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA

SO Bioorg. Med. Chem. (1998), 6(8), 1389-1401

CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

L31 ANSWER 4 OF 4 CA COPYRIGHT 2000 ACS

AN 123:160860 CA

TI Papaverine for the treatment of disorders associated with glutamatergic neurotransmission

IN Egyed, Andras; Gaal, Laszlo; Gigler, Gabor; Groo, Dora; Gyertyan, Istvan; Simo, Annamaria; Szemerédi, Katalin; Mandi, Attila

PA Egis Gyogyszergyar Rt., Hung.

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519173	A1	19950720	WO 1995-HU1	19950113
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	HU 71408	A2	19951128	HU 1994-96	19940114
	AU 9515441	A1	19950801	AU 1995-15441	19950113
PRAI	HU 1994-96		19940114		
	WO 1995-HU1		19950113		

=> d 131 2 all

L31 ANSWER 2 OF 4 CA COPYRIGHT 2000 ACS

AN 131:725 CA

TI Inhibitors of nitric oxide synthase, proinflammatory cytokine inhibitors,
and therapeutic use
IN Singh, Inderjit
PA Medical University of South Carolina, USA
SO PCT Int. Appl., 209 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K045-00
ICS C12N009-99; C12Q001-26; C12Q001-34
CC 1-12 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926657	A1	19990603	WO 1998-US25360	19981125
	W: AU, CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9915393	A1	19990615	AU 1999-15393	19981125
PRAI	US 1997-66839		19971125		
	US 1997-66295		19971125		
	WO 1998-US25360		19981125		
AB	Methods are disclosed for the inhibition of inducible nitric oxide synthesis (iNOS) and the prodn. of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compds. lovastatin, sodium phenylacetate, FPT inhibitor II, N-acetyl cysteine, and cAMP.				
ST	inducible NO synthase inhibitor therapeutic; X linked adrenoleukodystrophy NO synthase inhibitor; multiple sclerosis NO synthase inhibitor; Alzheimer disease NO synthase inhibitor; septic shock NO synthase inhibitor; lovastatin NO synthase cytokine inhibition; sodium phenylacetate NO synthase cytokine inhibition; FPT inhibitor II NO synthase cytokine inhibition; acetylcysteine NO synthase cytokine inhibition; cyclic AMP NO synthase cytokine inhibition				
IT	Transcription factors RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (NF-.kappa.B (nuclear factor .kappa.B); inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				
IT	Signal transduction, biological (Ras/Raf/MAP kinase pathway inhibitors; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				
IT	Farnesylation (Ras; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				
IT	Gene, animal RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (X-ALD; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				
IT	Brain, disease (X-linked adrenoleukodystrophy; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				
IT	Encephalomyelitis (autoimmune; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				
IT	Nerve, disease (demyelination; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)				

IT Ras proteins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (farnesylation; inducible nitric oxide synthase inhibitors,
 proinflammatory cytokine inhibitors, and therapeutic use)

IT mRNA
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (iNOS; inducible nitric oxide synthase inhibitors, proinflammatory
 cytokine inhibitors, and therapeutic use)

IT Anti-**Alzheimer's** agents
 Anti-inflammatory agents
 Apoptosis
 Astrocyte
 Drug interactions
 Drug screening
 Macrophage
 Multiple sclerosis
 Neuroglia
 Oligodendrocyte
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Lipopolysaccharides
 RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Ceramides
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Cytokines
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Interleukin 1.beta.
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Interleukin 2
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Interleukin 6
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Interleukin 8
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Sphingomyelins
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Tumor necrosis factors
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine
 inhibitors, and therapeutic use)

IT Peritoneum
 (macrophage; inducible nitric oxide synthase inhibitors,
 proinflammatory cytokine inhibitors, and therapeutic use)

IT Neuroglia
 (microglia; inducible nitric oxide synthase inhibitors,
 proinflammatory

cytokine inhibitors, and therapeutic use)

IT Myelin
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (myelinolytic inflammation; inducible nitric oxide synthase inhibitors,
 proinflammatory cytokine inhibitors, and therapeutic use)

IT Macrophage
 (peritoneal; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT Antioxidants
 (pharmaceutical; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT Shock (circulatory collapse)
 (septic; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT Drug interactions
 (synergistic; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT Fatty acids, biological studies
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (very-long-chain; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT Oxidation
 (.beta.-; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT Interferons
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (.gamma.; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT 9025-75-6
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1 and 2a, inhibitors; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT 103171-49-9, Ras kinase 142243-02-5, MAP kinase 144378-33-6, Raf kinase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (Ras/Raf/MAP kinase pathway inhibitors; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT 142008-29-5, Protein kinase A
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (enhancers and inhibitors, including myristoylated PKI; inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT 10102-43-9, Nitric oxide, biological studies
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT 56-25-7, Cantharidin 61-82-5, 1H-1,2,4-Triazol-3-amine 7683-59-2, Isoproterenol 7722-84-1, Hydrogen peroxide, biological studies 10465-78-8, Diamide 14333-18-7, Ortho-vanadate 28822-58-4, 3-Isobutyl-1-methylxanthine 51630-58-1, Fenvalerate 52315-07-8, Cypermethrin 52918-63-5, Deltamethrin 64657-18-7,

1,9-Dideoxyforskolin 77238-39-2, Microcystin 78111-17-8, Okadaic acid 83730-53-4 101932-71-2, Calyculin A 127243-85-0, H-89 151606-30-3, Dephostatin
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (inducible nitric oxide synthase inhibitors, proinflammatory cytokine inhibitors, and therapeutic use)

IT 60-92-4, Cyclic AMP

RL: BAC (Biological activity or effector, except adverse); BPR
(Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
USES (Uses)
(inducible nitric oxide synthase inhibitors, proinflammatory cytokine
inhibitors, and therapeutic use)

IT 58-55-9, Theophylline, biological studies 58-74-2 60-92-4D,
Cyclic AMP, derivs. 103-82-2, Phenylacetic acid, biological studies
103-82-2D, Phenylacetic acid, derivs. 114-70-5, Sodium phenylacetate
114-70-5D, Sodium phenylacetate, derivs. 616-91-1, N-Acetylcysteine
616-91-1D, N-Acetylcysteine, derivs. 1821-12-1, 4-Phenylbutyric acid
2627-69-2 2627-69-2D, derivs. 23583-48-4, 8-Bromo-cAMP 25769-03-3,
1-Pyrrolidinecarbodithioic acid 25769-03-3D, 1-Pyrrolidinecarbodithioic
acid, derivs. 61413-54-5, Rolipram 66575-29-9, Forskolin
66575-29-9D, Forskolin, derivs. 73573-88-3, Mevastatin 73573-88-3D,
Mevastatin, derivs. 75330-75-5, Lovastatin 75330-75-5D, Lovastatin,
derivs. 212766-19-3, FPT inhibitor II 212766-19-3D, FPT inhibitor II,
derivs.

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(inducible nitric oxide synthase inhibitors, proinflammatory cytokine
inhibitors, and therapeutic use)

IT 70-18-8, Reduced glutathione, biological studies 112-85-6, Docosanoic
acid 506-46-7, Hexacosanoic acid 557-59-5, Tetracosanoic acid
125978-95-2, Nitric oxide synthase

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(inducible nitric oxide synthase inhibitors, proinflammatory cytokine
inhibitors, and therapeutic use)

IT 13058-04-3, Farnesyl pyrophosphate

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); BIOL (Biological study)
(inhibitors; inducible nitric oxide synthase inhibitors,
proinflammatory cytokine inhibitors, and therapeutic use)

IT 9024-66-2, Mevalonate pyrophosphate decarboxylase 9028-35-7, HMG-CoA
reductase 9036-21-9, Cyclic AMP phosphodiesterase 79747-53-8, Protein
tyrosine phosphatase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; inducible nitric oxide synthase inhibitors,
proinflammatory cytokine inhibitors, and therapeutic use)

IT 172522-01-9, AMP-activated protein kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stimulators; inducible nitric oxide synthase inhibitors,
proinflammatory cytokine inhibitors, and therapeutic use)

IT 150-97-0

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis, inhibitors; inducible nitric oxide synthase inhibitors,
proinflammatory cytokine inhibitors, and therapeutic use)

RE.CNT 6
RE
(1) Denhardt; US 5695761 A 1997 CA
(2) Gross; US 5545625 A 1996
(3) Harrison; US 5498539 A 1996 CA
(4) Pahan; Increasing cAMP Attenuates Induction of Inducible Nitric-oxide
Synthase in Rat Primary Astrocytes 1997, V272(12), P7788
(5) Pahan; Journal Clinical Investigation 1997, V100, P2671 CA
(6) Societe De Conseils De Recherches Et D'Application Scientifiques; WO
98/09653 A1 1998 CA

=> s 127 and 110

20 L10

L32

0 L27 AND L10

=> d his

(FILE 'HOME' ENTERED AT 15:24:57 ON 16 AUG 2000)

FILE 'REGISTRY' ENTERED AT 15:25:53 ON 16 AUG 2000

L1 4 S BEPRIDIL
L2 22 S VERAPAMIL
L3 32 S NIFEDIPINE
L4 5 S NISOLDIPINE
L5 0 S THEPHYLLINE
L6 2485 S THEOPHYLLINE
L7 1 S SEMECARPUS ANACARDIUM
L8 74 S VITAMIN E
L9 162 S PAPAVERINE
L10 3 S DESDANINE

FILE 'CA' ENTERED AT 15:31:12 ON 16 AUG 2000

E ALTZHEIMER
E ALZHEIMER
L11 15731 S E3-E5
E DEMENTIA
L12 4671 S E3-E6
E SENILE
L13 17527 S E3 OR L11
L14 2881 S L12 AND L13
L15 464 S L1
L16 0 S L15 AND L14
L17 0 S L1 AND L14
L18 1 S L2 AND L14
L19 0 S L1 AND L11
L20 1 S L3 AND L14
L21 1 S L4 AND L14
L22 3 S L6 AND L14
L23 5 S L4 AND L11
L24 4 S L23 NOT L21
L25 20 S L6 AND L11
L26 17 S L25 NOT L22
L27 16091 S L14 OR L11
L28 0 S L7 AND L27
L29 0 S L7
L30 94 S ~~L8 AND L11~~
L31 4 S L27 AND L9
L32 0 S L27 AND L10

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

78.12

TOTAL

SESSION

137.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.65

-2.65

STN INTERNATIONAL LOGOFF AT 15:51:13 ON 16 AUG 2000

AN 117:126120 CA
 TI Vitamin E protects nerve cells from amyloid .beta. protein toxicity
 AU Behl, Christian; Davis, John; Cole, Greg M.; Schubert, David
 CS Salk Inst. Biol. Stud., San Diego, CA, 92186-5800, USA
 SO Biochem. Biophys. Res. Commun. (1992), 186(2), 944-50
 CODEN: BBRC9; ISSN: 0006-291X
 DT Journal
 LA English
 CC 4-3 (Toxicology)
 Section cross-reference(s): 6, 14
 AB Amyloid .beta. protein (ABP) and an internal fragment encompassing residues 25 to 35 (.beta.25-35) are cytotoxic to a clone of PC12 cells at concns. above 1x10-9M and to several other cell lines at higher concns. Between 10-9 and 10-11M .beta.25-35 protects PC12 cells from glutamate toxicity. The antioxidant and free radical scavenger vitamin E inhibits ABP-induced cell death. These results have implications regarding the prevention and treatment of **Alzheimer's** disease.
 ST amyloid toxicity nerve vitamin E
 IT Nerve, toxic chemical and physical damage
 (amyloid .beta.-protein toxicity to, vitamin E effect on, fragment toxicity in relation to)
 IT Proteins, specific or class
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (amyloid A4, toxicity of, to nerve, vitamin E effect on, fragment toxicity in relation to)
 IT 121-79-9, Propyl gallate **1406-18-4**, Vitamin E 9061-61-4, Nerve growth factor
 RL: BIOL (Biological study)
 (amyloid .beta.-protein toxicity to nerve in relation to)
 IT 56-86-0, Glutamic acid, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (tox

AN 118:247608 CA
 TI Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E
 AU Maneesub, Yawadee; Sanvarinda, Yupin; Govitrapong, Piyaarat
 CS Inst. Sci. Technol. Dev., Mahidol Univ., Thailand
 SO Neurochem. Int. (1993), 22(5), 487-91
 CODEN: NEUIDS; ISSN: 0197-0186
 DT Journal
 LA English
 CC 1-12 (Pharmacology)
 AB It has been suggested that the activity of the enzyme responsible for the synthesis of acetylcholine, choline acetyltransferase (ChAT), is substantially reduced in the neocortex and hippocampus of **Alzheimer's** and other aging brains. d-.alpha.-Tocopherol (vitamin E), a free radical scavenger fat-sol. vitamin, was utilized in the present study to det. whether its supplementation in aging and ethylcholine mustard aziridinium (AF64A)-lesioned rats would improve the cholinergic hypofunction. Vitamin E (given 24 h and 15 min prior to AF64A administration) significantly ($P < 0.01$) reversed the effect of AF64A in hippocampal choline acetyltransferase activity, but it did not cause any change of this enzyme activity in other brain regions (striatum and frontal cortex), nor did it cause any significant change after 30-day daily treatment in AF64A-lesioned rats. Furthermore, vitamin E (50 mg/kg, i.p. for 30-day treatment) significantly ($P < 0.01$) partially restored the enzyme activity in striatum of aging (20-28 mo old) rats. The present result indicates that vitamin E can partly restore the hypofunction of the cholinergic system in aging and partly prevent the toxicity in AF64A-lesioned rats.
 ST brain lesion cholinergic deficit vitamin E; aging brain cholinergic deficit vitamin E; choline acetyltransferase brain lesion vitamin E
 IT Senescence
 (brain choline acetyltransferase deficit in, vitamin E restoration of)
 IT Brain, disease
 (lesion, choline acetyltransferase deficit in, vitamin E restoration of, senescence in relation to)
 IT 59-02-9, d-.alpha.-Tocopherol
 RL: BIOL (Biological study)
 (choline acetyltransferase deficit in brain lesions restoration by, senescence in relation to)
 IT 9012-78-6, Choline acetyltransferase
 RL: BIOL (Biological study)
 (decrease of, in brain lesions, vitamin E partial restoration of, senescence in relation to)